CANCER RES 润色咨询

CANCER RESEARCH

出版年份：1941 年文章数：12632 投稿命中率： 开通期刊会员，数据随心看

出版周期：Semimonthly 自引率：2.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2021-07-29 123dfe03m73(暂无昵称)

    审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0
    偏重的研究方向：癌症
    经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and<The International Council for Harmonisation (ICH)> Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有<The Declaration of Helsinki>和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢...

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2021-08-25 PILIXIA

    这个杂志是不是一般都会送外审

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2021-08-25 PILIXIA

    eeeeeee

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-04-08 tomsyu

    今年估计能到几分啊？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-03-15 zyg1

    另外一篇，也是cr，说的一审大概2-4周。2审1-2周doctor杨 2020-03-11 00:00:00 发表:
    我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊

    doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-05-26 1209b38am73暂无昵称

    你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2021-01-04 1215c911m91暂无昵称

    刚投了一篇……等待中

    1

    展开1条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-07-28 silent111

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享：
    Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-07-24 silent111

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享： 请问，你的文章现在什么状态？谢谢。
    2020-07-09
    对的我
    我投了一篇，已经4天了，还停留在initial QC阶段，正常不。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1003674, encodeId=e40e10036e4e3, content=审稿速度:3.0 | 投稿命中率:25.0 | 审稿费用:500.0 | 版面费用:3500.0<br>偏重的研究方向：癌症<br>经验分享：大家不要“50步笑百步”了。本期刊因为上海陈竺和张亭栋2001的一篇“AS2O3治疗急性早幼粒细胞白血病”2018获国际大奖“舍贝里奖/瑞典与诺奖平级别”所以国内风向突变，这也有情可原之。cancer research对实验室大数据太过于看重而忽略临床，欧美从1775-2020的245年中尤其是UICC从2016-2018——战胜癌症，We can, I can,2019-2021还不是一夜回到解放前=UICC主题：关爱患者共同抗癌！！！欧美西方除了“乡村医生爱德华詹纳（Edward Jenner）and&lt;The International Council for Harmonisation (ICH)&gt; Good Clinical Practice (GCP) guidelines. 甚至连他写的《小册子》也没有出版社给她发表，可他就在1790年用牛痘消灭‘天花’（没有实验室大数据、没有医学会评估论证、也没有“生命科学研究规则”、更没有&lt;The Declaration of Helsinki&gt;和）...遗憾地是他不是教授也不是院士”...搁在今天也不例外！除此之外欧美日奥加养活了几近一个亿的生物医学家（医生）、伯爵和美国大亨=有什么用处呢？真是...罢罢罢..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=800b2444289, createdName=123dfe03m73(暂无昵称), createdTime=Thu Jul 29 20:49:15 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011339, encodeId=7dbd101133912, content=这个杂志是不是一般都会送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:58:25 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011337, encodeId=f2f0101133e7e, content=eeeeeee, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01e62473238, createdName=PILIXIA, createdTime=Wed Aug 25 12:46:48 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=588452, encodeId=f45858845260, content=今年估计能到几分啊？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/01/26/7fefbc5f6b3c3f8bead162d3b71ae939.jpg, createdBy=03a685339, createdName=tomsyu, createdTime=Wed Apr 08 00:00:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=586666, encodeId=fbc95866664c, content=另外一篇，也是cr，说的一审大概2-4周。2审1-2周<span class="quote">doctor杨 2020-03-11 00:00:00 发表:<br>我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊</span>, beContent=doctor杨 2020-03-11 00:00:00 发表: 我也是正在二审underreview，已经20多天了，我看平均得1个月吧，希望别拒啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=0e651997208, createdName=zyg1, createdTime=Sun Mar 15 00:00:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=600617, encodeId=dd2560061e36, content=你好，我想请问投稿的前辈们，在投稿过程中有主动选择editor吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=151, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee212193399, createdName=1209b38am73暂无昵称, createdTime=Tue May 26 23:35:04 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913610, encodeId=c77791361063, content=刚投了一篇……等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=116, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc5d2248408, createdName=1215c911m91暂无昵称, createdTime=Mon Jan 04 15:39:25 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804832, encodeId=98db804832de, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享： <br>Dr. X. 你好，问一下。你的文章怎么3稿呢？第一稿的Decision Pending 2020-04-06 17:45:32 是杂志编辑的意见么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Tue Jul 28 06:50:52 CST 2020, time=2020-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=804356, encodeId=d9c4804356b0, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享： 请问，你的文章现在什么状态？谢谢。<br>2020-07-09<br>对的我 <br>我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47a61663560, createdName=silent111, createdTime=Fri Jul 24 18:34:32 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=801823, encodeId=1174801823cf, content=我投了一篇，已经4天了，还停留在initial QC阶段，正常不。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=88581727518, createdName=对的我, createdTime=Thu Jul 09 10:08:50 CST 2020, time=2020-07-09, status=1, ipAttribution=)]
    2020-07-09 对的我

    我投了一篇，已经4天了，还停留在initial QC阶段，正常不。

    0

共364条页码: 6/37页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分